Jacobs Levy Equity Management
SRPT icon

Jacobs Levy Equity Management’s Sarepta Therapeutics SRPT Stock Holding History

Jacobs Levy Equity Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-372,637
Closed -$8.11M – 1075
2026
Q1 		$8.11M Sell
372,637
-180,742
-33% -$3.5M 0.03% 339
2025
Q4 		$11.9M Buy
553,379
+291,048
+111% +$6.13M 0.05% 279
2025
Q3 		$5.06M Buy
262,331
+17,798
+7% +$317K 0.02% 424
2025
Q2 		$4.18M Buy
+244,533
New +$10.4M 0.02% 480
2024
Q4 		– Sell
-753,845
Closed -$94.1M – 1037
2024
Q3 		$94.1M Buy
753,845
+63,437
+9% +$8.77M 0.36% 68
2024
Q2 		$109M Buy
690,408
+110,771
+19% +$14.2M 0.45% 52
2024
Q1 		$75M Buy
579,637
+120,535
+26% +$14.8M 0.34% 73
2023
Q4 		$44.3M Buy
459,102
+61,646
+16% +$5.91M 0.22% 104
2023
Q3 		$48.2M Sell
397,456
-48,117
-11% -$5.44M 0.29% 78
2023
Q2 		$51M Sell
445,573
-36,423
-8% -$4.7M 0.29% 85
2023
Q1 		$66.4M Buy
481,996
+6,095
+1% +$791K 0.41% 56
2022
Q4 		$61.7M Sell
475,901
-26,292
-5% -$3.05M 0.42% 59
2022
Q3 		$55.5M Buy
502,193
+66,383
+15% +$6.69M 0.44% 52
2022
Q2 		$32.7M Sell
435,810
-2,235
-0.5% -$164K 0.25% 110
2022
Q1 		$34.2M Buy
438,045
+9,311
+2% +$713K 0.23% 109
2021
Q4 		$38.6M Buy
428,734
+330,949
+338% +$28.3M 0.26% 102
2021
Q3 		$9.04M Buy
97,785
+4,835
+5% +$372K 0.06% 321
2021
Q2 		$7.23M Buy
92,950
+3,953
+4% +$300K 0.05% 365
2021
Q1 		$6.63M Buy
+88,997
New +$8.21M 0.05% 373
2020
Q3 		– Sell
-2,943
Closed -$472K – 1102
2020
Q2 		$472K Buy
+2,943
New +$400K 0.01% 797
2016
Q3 		– Sell
-18,300
Closed -$349K – 1122
2016
Q2 		$349K Buy
+18,300
New +$339K 0.01% 849

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Jacobs Levy Equity Management's SRPT Position: Q2 2026 in Review

Jacobs Levy Equity Management sold out of Sarepta Therapeutics (SRPT) in Q2 2026, closing a stake of 372,637 shares — an estimated $8.11M sold.

Jacobs Levy Equity Management first reported a position in SRPT in Q2 2016 and held it in 21 quarters. The position peaked at $109M in Q2 2024. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Jacobs Levy Equity Management reported no remaining Sarepta Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 372,637 Sarepta Therapeutics shares in Q2 2026, an estimated $8.11M.
  • Jacobs Levy Equity Management first reported a position in Sarepta Therapeutics in Q2 2016 and held it in 21 quarters.
  • Jacobs Levy Equity Management's Sarepta Therapeutics position peaked at $109M in Q2 2024.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2026, filed 14 Aug 2026.